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What Are Blastocystis spp.?
Blastocystis spp. belong to the phylum Stramenopila, a
complex and heterogeneous evolutionary assemblage of hetero-
trophic and photosynthetic protozoa [1]. Interestingly, this is the
only stramenopile living in the lower digestive tract of humans,
and it also lives in other mammals, birds, reptiles, amphibians,
and insects [1]. Even though isolates were reported to be
morphologically indistinguishable, an extensive genetic varia-
tion among isolates from both humans and animals has been
observed. Thirteen subtypes (ST1–ST13), with the first nine
being found in humans, have been identified based on genes
coding for the small-subunit ribosomal RNA [2]. Preferential
repartition of STs exists among animals that appear to
constitute the main reservoir for environmental dissemination
and human contamination [1].
Four forms of Blastocystis spp. (vacuolar, granular, amoeboid,
and cyst) were described in stools and/or in vitro cultures [1].
Studies in animals demonstrated that the water- and environmen-
tally resistant infective cyst undoubtedly represents the transmis-
sible stage of this parasite [1]. Blastocystis spp. prevalence in
humans often exceeds 5% in industrialized countries and can
reach as high as 76% in developing countries [1,3]. However,
prevalence data are largely dependent on the methods used for
detection, quantitative PCR being the most sensitive method,
meaning that infections by Blastocystis spp. are likely underesti-
mated [4].
Lately, Blastocystis spp. have been included in the water
sanitation and health programs of the World Health Organization
[5]. Increasing interest of scientific and medical communities for
Blastocystis spp. was coupled with new data about epidemiology,
pathogenicity, and, more recently, the first whole genome of a
human isolate. Accumulating in vivo, in vitro, and in silico data
has enabled researchers to assess the potential impact of Blastocystis
spp. in human health.
Are Blastocystis spp. Pathogens?
In vivo endoscopy and biopsy analyses in symptomatic patients
indicated that Blastocystis spp. do not invade the colonic mucosa,
but lead to disturbances on the barrier function and permeability
[1,6]. Experiments on immunocompetent BALB/c mice revealed
intense inflammatory-cell infiltration in the mucosa of some
specimens, but not in all mice, suggesting that some host factors
could be involved [1]. Subsequently, the infectivity of human
isolates obtained from both asymptomatic and symptomatic
patients on rats was assessed by Hussein et al. [7]. Interestingly,
the moderate and severe degrees of pathological changes were
only found in rats infected by isolates from symptomatic patients,
and differences in severity were observed among the different STs
of Blastocystis, suggesting the existence of some more virulent
strains.
To understand cellular mechanisms, in vitro experiments were
performed to investigate the cytopathic effects of Blastocystis spp.
on mammalian cell cultures (Figure 1). A first study showed in
the rat epithelial cell line IEC-6 that Blastocystis ST4 can induce
apoptosis in a contact-independent manner, increasing epithelial
permeability [8]. The pro-inflammatory effect of Blastocystis ST1
culture filtrates was demonstrated on HT-29 and T-84 human
colonic epithelial cells with production of interleukin 8 (IL-8)
and granulocyte-macrophage colony stimulating factor (GM-
CSF) [1]. Cysteine proteases of Blastocystis ST4 were shown to
induce IL-8 production via an NF-kB pathway [9]. Proteases
released in culture supernatants of both Blastocystis ST4 and
ST7 were also shown to be able to cleave human-secreted
immunoglobulin A (IgA) and then modulate the immune
response of the host [1]. A surface-located cysteine protease
was recently shown to be involved in a pro-survival role in
Blastocystis ST7 and may activate other proteases [10]. Never-
theless, in vitro studies are limited by the lack of tools to study
Blastocystis spp. Indeed, few strains of Blastocystis spp. are
available in axenic cultures, and growth rates in culture are
fluctuating and quite low. In addition, growth of this parasite is
realized in anaerobic chambers that limit the possibility of long-
term exposure in cellular models.
Is There a Link between Blastocystis spp. and IBS?
Some studies have suggested an association of Blastocystis spp.
with acute or chronic digestive disorders such as irritable bowel
syndrome (IBS) [1]. IBS is a functional gastrointestinal disorder
characterized by abdominal discomfort and/or pain associated
with changes in bowel habits, affecting 5%–24% of people in
industrialized countries with impairment on quality of life [11]. In
1997, Hussain et al. highlighted that sera from IBS patients were
characterized by higher IgG antibody levels to Blastocystis spp.
when compared to healthy populations [12]. However, the first
relevant epidemiological report about a possible link between
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Giacometti et al. [13]. When comparing the prevalence of
Blastocystis spp. in individuals with gastrointestinal symptoms and
classified as affected or not by IBS, the authors found that it was
significantly present in IBS patients. Other more recent studies
also argued for a higher prevalence of Blastocystis spp. among IBS
patients (Table 1) compared to healthy populations or to patients
suffering from other gastrointestinal disorders [3,13–17]. Howev-
er, three studies failed to demonstrate an association between
Blastocystis spp. and IBS [18–20]. Possible explanations could be
the small IBS cohort studied or the parasitological diagnostic
methods used. Two of these three studies were from Thailand and
one from Mexico, whereas studies arguing for a link between
Blastocystis spp. and IBS were from the Middle East (Table 1) and
Europe. IBS is a functional disorder of multifactorial origin, and
some genetic, environmental, and microbiological factors could
also explain this discrepancy. Nevertheless, overall studies missed
an opportunity to provide a therapeutic trial with a follow up of
IBS symptoms.
Recent studies suggest that visceral pain associated with IBS
could be explained by alterations of the epithelial barrier, resulting
in bowel motility and sensitivity disorders (Figure 1). Indeed, in
vitro studies on colonic biopsies from patients with IBS showed an
increase of paracellular permeability associated with perturbations
of tight junctions (TJs) [21]. On the other hand, it is now well
recognized that there is a low-grade inflammation of the mucosa in
IBS patients [22]. Then, protease-activated receptor type 2 (PAR-
2) was proposed to be involved in both an increase of permeability
and low-grade inflammation [23]. PAR-2 are activated by serine-
proteases that cleave the N-terminal domain of the receptor.
Then, the released peptide may act as a ligand and turn on the
receptor to enhance TJ opening and trigger inflammation.
Increase of paracellular permeability allows diffusion of both
antigens and bacteria to sub-mucosa, participating in inflamma-
tion. PARs are also present at the surface of intestinal neurons.
The activation of some members of the PAR family could
contribute to abdominal pain [24]. Studies also showed that stools
from IBS patients present higher proteolytic activity than healthy
Figure 1. Hypothetical model of pathogeny for Blastocystis spp. from genomic (*) and experimental (**) data. Potential link to IBS
pathophysiology mechanisms (in red). IgA, immunoglobulin A; NRPS, non-ribosomal polyketide synthase; PAR, protease-activated receptor; PKS,
polyketide synthase.
doi:10.1371/journal.ppat.1002545.g001
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supernatants from axenic cultures of both Blastocystis ST4 and ST7
[1]. This is supported by the prediction of 22 secreted proteases
from genomic data of Blastocystis ST7 (detailed below) [26]. These
experimental and genomic data suggest a possible involvement of
parasite proteases in gastrointestinal disturbances. Thus, proteases
from bacteria or Blastocystis spp., such as metalloproteases,
cysteine, or serine proteases, could play a key role in IBS genesis
[24]. This perturbation could be linked to a modification of lumen
microbiota in IBS patients compared to healthy patients [27].
Then, dysbiosis may take part in low-grade inflammation of the
mucosa and IBS symptoms.
How Can Genomic Data Support the Blastocystis
spp./IBS Association?
The whole genome of a Blastocystis ST7 isolate has been
sequenced [26]. Interestingly, candidate proteins potentially
involved in the pathogenicity of Blastocystis spp. were identified
by in silico analyses of the predicted proteome and secretome
(Figure 1).
Blastocystis ST7 likely uses hydrolases to attack host tissues for its
nutrient supply. Fucosidase, hexosaminidase, and b-galactosidase
were identified in the Blastocystis ST7 predicted secretome.
Blastocystis ST7 may participate in this process by degrading host
glycoproteins, especially those that constitute the mucus [26]. In
addition, cysteine proteases could also degrade mucins [24]. Thus,
these enzymes may allow Blastocystis spp. to use mucus as a
carbohydrate and protein source and enable them to survive
within the intestinal environment by creating their own micro-
environment. Interestingly, 22 proteases, including 20 cysteine
proteases, one serine protease, and one aspartic protease, were
predicted to be secreted [26]. The impairment of mucus may be
the initial step to inflammatory and allergic disturbance caused by
chronic exposure to luminal antigens. Then, proteases from
Blastocystis spp. and/or gut bacteria can also target receptors at the
intestinal cell surface. These proteolytic enzymes are known to be
involved in paracellular permeability, inflammation, and hyper-
sensitivity [24]. The Blastocystis ST7 serine protease could therefore
have the ability to target PAR-2 (Figure 1), inducing inflammation
and TJ disruption as frequently seen in IBS. Once the TJs are
opened, luminal proteases can have access to submucosal ganglia,
activate PARs on enteric neurons (Figure 1), and be responsible for
hypersensitivity in IBS patients [24]. Penetration of luminal
bacteria or antigens could participate in the establishment of a
chronic low-grade inflammation in submucosa by stimulation of
innate immunity.
Blastocystis ST7–secreted glycosyltransferases could also partic-
ipate in TJ disruption in IBS. This can be illustrated by the
lymphostatin (toxin) of Citrobacter rodentium, which possesses a
glycosyltransferase activity that primarily influences localization of
ZO-1 and occludin at intestinal cell TJs, compromising epithelial
barrier function [24]. This is also the case for Clostridium spp.,
which exhibit toxins with glycosyltransferase activities [24]. These
proteins act by inactivating Rho proteins that are known to be
important in maintaining TJs.
Concerning the intestinal protease balance that regulates gut
functioning, protease inhibitors released by enteric pathogens or
parasites can modulate the activity of host proteases and disturb
intestinal homeostasis [28]. Genes coding for protease inhibitors
are also present in the Blastocystis ST7 genome, and some are
predicted to be secreted, including cystatin, type 1-protease
inhibitor, and endopeptidase inhibitor-like protein [26]. More-
over, dysbiosis was shown to occur during IBS [27]. Genomic data
revealed that a polyketide synthase (PKS) and a non-ribosomal
polyketide synthase (NRPS) are present in Blastocystis ST7. These
enzymes are known to produce non-ribosomal peptides and
polyketides with various biological properties, such as antibiotics
or immunomodulatory molecules that could participate in
dysbiosis and inflammation [29].
Finally, we can assume that Blastocystis spp.–secreted proteins
have the potential to modulate host defenses and to facilitate
nutrient acquisition and parasite colonization. Moreover, Blas-
tocystis spp. would be able to alter integrity of gut epithelia and
probably participate in dysbiosis.
What Is Needed to Improve the Knowledge on
Blastocystis spp. Biology?
A consortium including the most relevant researchers on this
topic is being set up. The first aim is to develop efficient
standardized tools to study Blastocystis spp., including the
improvement of cultural methods (in particular, axenization
protocols of the other STs) and development of new molecular
Table 1. Summary of studies investigating the association between Blastocystis spp. and IBS.
Studies Country Diagnostic Method IBS Patients Control Group
Prevalence n (%) Criteria
b Prevalence n (%) Population
Giacometti et al. [13] Italy Trichrome stain 15/81 (18.5)
a Rome 23/307 (7.5) GD
Yakoob et al. [17] Pakistan Culture 44/95 (46)
a Rome II 4/55 (7) GD
Tungtrongchitr et al. [20] Thailand Culture 8/59 (13.6) Rome II 3/25 (12) Healthy
Yakoob et al. [15] Pakistan Culture 95/158 (60)
a Rome III 38/157 (24) Healthy, GD
Surangsrirat et al. [19] Thailand Culture 11/66 (16.7) Rome II 6/60 (10) GD
Yakoob et al. [16] Pakistan Culture 90/171 (53)
a Rome III 25/159 (16) Healthy
Dogruman-Al et al. [3] Turkey Lugol stain 8/21 (38)
a Rome III 5/43 (11.6) Healthy
Ramirez-Miranda et al. [18] Mexico Flotation method n.a./115 (15.7) Rome III n.a./209 (12) GD
Jimenez-Gonzalez et al. [14] Mexico Flotation method 14/45 (31.1)
a Rome III 6/45 (13.3) GD
aStudies concluding to an association between Blastocystis spp. and IBS.
bRome criteria used to diagnose IBS.
GD, gastrointestinal disorders; n.a., not available.
doi:10.1371/journal.ppat.1002545.t001
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pathogenicity needs to be elucidated, notably by sequencing the
whole genome of other STs. Comparative genomic analyses will
then be useful for both identification and validation of in silico–
predicted virulence factors. Animal models are also needed to go
further in the understanding of the role of Blastocystis spp. in gut
dysfunctions. Another aim is to develop some reverse genetic tools
for functional characterization of genes of interest. Considering the
clinical implication of Blastocystis spp. in IBS, none of the published
studies provided complete clinical data about IBS classification
and Blastocystis STs. Thus, well-designed multi-centric studies are
required, and studies on Blastocystis spp. susceptibility to treatment
have to be used to suggest guidelines for the eradication of this
infection [30]. The role of Blastocystis spp. in dysbiosis and the
exact interactions with bacteria also have to be highlighted. This
approach seems more relevant because of the increasing interest in
microbiota disturbances in the genesis of various gastrointestinal
dysfunctions.
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